NICE Pans Roche’s Perjeta For Breast Cancer On Clinical, Cost Grounds
This article was originally published in The Pink Sheet Daily
Roche’s Perjeta suffered a knock-back in Europe when NICE said the clinical trial population was not wholly relevant to the patient population in the UK.
You may also be interested in...
A new leadership team at EMA to be unveiled in September; the death of Pierre Fabre leads to management restructuring at France's third largest pharma; Reinhardt to review strategy as he replaces Vasella at the Swiss multinational, Novartis; and more…
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).
NICE’s scientific advice program, now in its third year, may need refocusing and increased co-operation with regulators to appeal to small and medium-sized companies.